destiny-lung01: a practice-changing trial for nsclc
Published 2 years ago • 197 plays • Length 1:14Download video MP4
Download video MP3
Similar videos
-
5:08
should adaura trial results change practice in nsclc?
-
2:37
destiny-lung01: cohort expansion results
-
8:53
interim results from destiny-lung01: t-dxd in her2-overexpressing nsclc
-
6:29
dr saswata shah | primary data from destiny lung01 a phase 2 trial of trastuzumab derruxtecant dxd
-
3:16
adaura phase iii trial data: practice changing?
-
0:41
treatment options for metastatic non-small cell lung cancer with no actionable mutations in 1l
-
1:48
destiny lung 01 from #esmo21 presenter dr. stephen liu
-
1:10
‘mixed bag’: only a fraction of recent drug approvals in nsclc space ‘considered practice changing’
-
6:33
a practice change for alk lung cancer patients, alecensa for first line treatment
-
24:50
lung cancer asco 2024 practice changing highlights - discussion with dr. joshua sabari
-
3:58
antibody drug conjugates in lung cancer
-
0:50
targeted option for non-small cell lung cancer #2023 #oncology #lungcancer
-
4:17
nsclc trial updates at esmo 2022: adaura, destiny-lung02, kn189, kn407 & poseidon
-
0:58
first line treatment options for activating egfr non-small cell lung cancer | dr. alexander spira
-
1:00
treatment options for metastatic non-small cell lung cancer with actionable mutations in 1l
-
19:12
metastatic non-small cell lung cancer (nsclc) algorithm w/ targetable mutations- dr. jarushka naidoo
-
0:48
laura trial - osimertinib as consolidation in non-small cell lung cancer.
-
1:30
a shifting paradigm: lung cancer
-
0:54
lorlatinib for alk metastatic non-small cell lung cancer.